Selecta Biosciences, Inc. (SELB)
| Market Cap | 352.03M |
| Revenue (ttm) | 16.60M |
| Net Income (ttm) | -68.88M |
| Shares Out | 101.20M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | 69.93 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $3.11 |
| Previous Close | $2.98 |
| Change ($) | 0.13 |
| Change (%) | 4.36% |
| Day's Open | 2.96 |
| Day's Range | 2.91 - 3.18 |
| Day's Volume | 885,348 |
| 52-Week Range | 1.47 - 5.70 |
It may be time to buy Twitter, Inc. (NYSE:TWTR), Selecta Biosciences, Inc. (NASDAQ:SELB), and FARO Technologies, Inc. (NASDAQ:FARO) and the reasons why will be outlined below. Twitter is oversold and at...
WATERTOWN, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...
The progress of one of the company's clinical programs is being delayed.
Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences ...
– Methylmalonic Acidemia (MMA) program to become wholly-owned by Selecta –
WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 6.67% and 105.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...
- First-in-human dose-escalation study to evaluate ability of ImmTOR™ to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 -
Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...
WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector -
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy –
Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based cl...
- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8 alone –
WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...
Selecta was down due to unclear results from the COMPARE trial. Management attributes poor data to noncompliance due to covid-19, among other things.
SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company'...
The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript
Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.
WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based o...
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Selecta Biosciences (SELB) news for Monday includes insider buying from a Board of Directors member sending SELB stock higher. The post Selecta Biosciences News: SELB Stock Shoots 9% Higher on Insider B...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
These are the stocks seeing the most insider buying this week
In his weekly exclusive for Worldwide Exchange, Brian Sullivan highlights three stocks seeing the most insider buying this week, including some biotech names.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
Application of ImmTOR™ plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN )
With a market cap of $171 million (10/1/2020), Selecta Biosciences is a well positioned clinical-stage biotech company, focusing on immunogenicity.
Shares of Horizon Therapeutics PLC (NASDAQ: HZNP), which focuses on rare and rheumatic diseases, surged higher Thursday despite an absence of announcements from the biopharma. What Happened: Horizon sha...
Disappointing phase 2 data casts doubt on SEL-212's future.
STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the p...
All data consistent with stronger performance of SEL-212 versus pegloticase
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies base...
STOCKHOLM and WATERTOWN, Mass., Sept. 23, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the ...
STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commen...
WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies base...
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2020 Results - Earnings Call Transcript
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020.
Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.
WATERTOWN, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based...
In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based...
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based...
STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) today announced that the strategic licensing agreement with Selecta B...
Is (SELB) Outperforming Other Medical Stocks This Year?
These two healthcare stocks are risky, but they have much better chances of success than penny stocks.
About SELB
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropat... [Read more...]
| Industry Biotechnology | IPO Date Jun 22, 2016 |
| CEO Carsten Brunn | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol SELB |
Financial Performance
In 2020, SELB's revenue was $16.60 million, an increase of 148.57% compared to the previous year's $6.68 million. Losses were -$68.88 million, 24.4% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for SELB stock is "Buy." The 12-month stock price forecast is 8.00, which is an increase of 157.23% from the latest price.